本文目的是制备具有结肠靶向功能的高分子药物，以期为临床应用提供一种有效的给药途径。
The purpose of this paper is to prepare some colon-specific polymer drugs, in order to provide an effective method for the clinical application of 5-ASA.
药物的控制释放体系是生物医用材料研究领域的重要课题，其支撑点是要有性能良好的高分子药物载体。
The controlled drug release systems are an important research field in biomedical materials applications. Its effectiveness largely depends on the good properties of drug carriers.
生物可降解型高分子载体控制释放药物和生物可降解型高分子载体靶向药物是近年来高分子药物研究的重点。
Biodegradable macromolecule carried controlled drug releasing and biodegradable macromolecule carried targeted drug delivery are the focus of recent investigation in macromolecular medicine.
通过调节单体的投料比可方便的控制共聚物的组成，从而获得不同药物含量的高分子药物，且能应用于高分子复合药物的合成；
The composition of the copolymers can be controlled by adjusting the mol ratio of monomers attend the co-polymerization, so that polymeric drugs with various contents of drugs can be obtained.
本文主要介绍药物控制释放的种类、机理、高分子材料及其应用。
In this article, the types, mechanisms, materials and applications of the controlled release of drug are discussed.
该方法可应用于高分子材料，无机与有机以及药物与食品科学等领域。
The way may apply in the fields of high polymer materials, inorganic, organic, medicine and foodstuff science.
医用纳米高分子作为药物、基因传递和控释的载体，是一种新型的控释体系。
As a new drug and gene delivery carrier, medical polymer nanoparticles appear to be very promising and have been widely studied.
综述了可生物降解的高分子材料聚天各酰胺及其衍生物作为载体在药物控制释放中的应用。
The USES of biodegradable polymers poly-asparagine and its derivatives, as carriers in controlled drug release are reviewed.
目的：探讨壳聚糖在脑组织中的生物相容性，以期为临床提供可用于颅内植入化疗的药物缓释高分子载体。
OBJECTIVE:To explore the biocompatibility of chitosan in brain tissues in order to provide slow released macromolecule carrier for clinically used chemotherapy.
生物降解高分子材料具有良好的生物相容性和生物降解性而成为人们关注的药物控释材料。
Biodegradable polymers, which have many advantages such as biocompatibility and biodegradability, have been focused on as controlled drug materials.
阐述了高分子包囊的粒径、表面积、孔度、药物性能和药含量，以及高分子包囊材料的性能对药物释放行为的影响。
The effect of the size, surface area and porosity of particles, the property and content of drugs, as well as the properties of polymer on the drug release behavior of microcapsules are elucidated.
方法应用药物控制释放技术，采用生物降解高分子对药物进行包埋或微包囊。
Methods Using drug controlled release technique that to embed or microcapsulate the biological drug with biodegradable polymer.
在此基础上，概述了磁性高分子微球在磁性塑料、固定化酶、细胞分离和靶向药物等领域的应用情况，并对磁性高分子微球的未来研究方向进行了展望。
The applications of magnetic polymer microspheres in magnetic plastics, enzyme immobilization, cell separation and target drug etc. were also summarized, and the prospects of this field were analyzed.
研究结果表明：（1）通过先合成小分子药物单体，再进行聚合得到高分子载体药物的途径是可行的，且可使携药量得到极大程度的增加。
The results show as follows:(1)It is feasible to obtain polymeric carrier drugs by synthesizing unsaturated drug monomers firstly, then self-polymerizing and co-polymerizing them.
聚乳酸乙醇酸（PLGA）是一种可降解的高分子聚合物，其对药物具有缓释作用，且有较好的生物相容性。
PLGA is a kind of degradable high molecular polymer with good biocompatibility. Drug connected have the function of control release.
可生物降解高分子材料具有良好的生物相容性。聚合物和降解产物对机体毒副作用小，已成为微球等新药物剂型的重要载体材料。
Biodegradable polymer materials had good biocompatibility. Polymer and degradation product had small toxicity to the body, which become new drug major carriers of microsphere formulations.
按照上述的本发明方法，就可以用少量的水在短时间内简便地制造所需的含药物高分子微球。
According to the present invention, the desired polymeric microspheres loaded with drugs can be simply produced with a small amount of water in a short period of time.
目的用BPJ 10高分子材料制备的人工膜评价并预测药物透过皮肤的可行性。
OBJECTIVE To predict and evaluation the possibility of skin permeability of drug through the artificial membrane made of BPJ-10 polymer.
结果：通过调节药物浓度和不同高分子组合筛选出突释小，包封率高且缓慢释放的处方。
Results: By adjusting LDME concentration and different polymer combinations, we achieved microspheres with high encapsulation efficiency, low initial burst and sustained release.
雷帕霉素是一种抗增生型药物，丙烯酸树脂是一种通用的非降解型医用高分子材料，而PLGA是一种常用的可降解医用高分子材料。
Sirolimus is a kind of anti-proliferation drug, and acrylate resin is a kind of universal non-degradable biomaterial, moreover, PLGA is a kind of biodegradable medical polymer.
本发明涉及一种控释软膏组合基质及其制备方法。该软膏含有环糊精、药物、高分子材料和增塑剂。
The invention relates to a method for preparing control-release paste medium, comprising cyclodextrin, drug, macromolecule and elasticizer.
本发明涉及一种控释软膏组合基质及其制备方法。该软膏含有环糊精、药物、高分子材料和增塑剂。
The invention relates to a method for preparing control-release paste medium, comprising cyclodextrin, drug, macromolecule and elasticizer.
应用推荐